OR-USB-IF
16.7.2020 15:02:09 CEST | Business Wire | Press release
USB Implementers Forum (USB-IF), the support organization for the advancement and adoption of USB technology, today announced an updated USB Device Class Definition for MIDI Devices, Version 2.0 in support of MIDI 2.0 devices. The standard represents an industry-wide effort by the USB-IF, MIDI Manufacturers Association (MMA), and Association of Musical Electronics Industry (AMEI) to provide MIDI users with an expanded MIDI environment connected by USB.
“USB-IF is proud to support the MMA and AMEI by publishing an updated USB Device Class Specification for next-generation MIDI devices,” said Jeff Ravencraft, USB-IF President and COO. “USB has been an integral part of the MIDI environment over the past 20 years, and we look forward to seeing innovative new devices that are enabled by this updated specification.”
Mike Kent, Project Chair of the USB MIDI class specification and Chairman of the MMA's MIDI 2.0 Working Group, said, "This updated specification delivers many improvements that musicians and artists want from MIDI 2.0, including bidirectional communication, higher-speed throughput, more MIDI channels, accurate timing with dense MIDI streams, and backwards compatibility with MIDI 1.0 devices. The USB-IF's work is a major, and significant, step forward for MIDI 2.0."
The original USB Device Class Specification supporting MIDI 1.0 devices was published in 1999. Since then, USB MIDI has grown significantly and is now the most widely used transport for MIDI. The updated specification uses the new Universal MIDI Packet format over USB, and is designed to cover the widest range possible of MIDI applications and products. This USB specification is a key enabler for MIDI 2.0, supporting the inspiring features of MIDI 2.0 devices while integrating backward support for MIDI 1.0 devices.
Companies contributing to the updated specification include Apple Corporation, Knowles Corporation, Native Instruments, Roland Corporation, and Yamaha Corporation.
About the USB-IF
The non-profit USB Implementers Forum, Inc. was formed to provide a support organization and forum for the advancement and adoption of USB technology as defined in the USB specifications. The USB-IF facilitates the development of high-quality compatible USB devices through its logo and compliance program, and promotes the benefits of USB and the quality of products that have passed compliance testing. Further information, including postings of the most recent product and technology announcements, is available by visiting the USB-IF website at www.usb.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005214/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Brings Mobile-First Monetization Expertise to Gamesforum Barcelona 2026, Where Europe's Mobile Gaming Leaders Gather to Solve the Industry's Toughest Growth Challenges9.2.2026 20:30:00 CET | Press release
Platform That Powers 1,500+ Game Developers Across 200+ Geographies Expands Commerce, Payment, and Distribution Infrastructure to Adjacent Creative Industries Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its participation in Gamesforum Barcelona 2026, taking place Feb.10-11 at the InterContinental Hotel in Barcelona. This event brings together Europe's sharpest minds in mobile gaming for practical, data-driven sessions focused on what actually works in today's hypercompetitive mobile landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209301026/en/ (Graphic: Xsolla) With over 600 professionals from Europe's top publishers, ad networks, and studios in attendance, Gamesforum Barcelona has earned its reputation as the place where mobile gaming's most pressing problems get solved: How do you scale profitably? How do you retain players in satur
Beast Industries Acquires Step, Expanding its Platform to Include Financial Services9.2.2026 18:30:00 CET | Press release
This strategic acquisition brings innovative fintech capabilities to Beast Industries’ growing global platform, combining technology, content, and purpose to redefine financial services for the next generation Beast Industries, the largest and most innovative creator based platform in the world, today announced the acquisition of Step, a financial technology company dedicated to making financial literacy and money management accessible to all. This acquisition marks a significant milestone for Beast Industries, bringing together Step's robust technology platform and full-stack fintech team with Beast Industries’ extensive audience reach and proven track record in philanthropic initiatives. Together, the combined organization will deliver innovative solutions that make financial wellness achievable for people at every step of their life journey. "Financial health is fundamental to overall wellbeing, yet too many people lack access to the tools and knowledge they need to build financial
Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 15:26:00 CET | Press release
Align Partners underscores DBI’s persistent undervaluation (0.40x Adjusted PBR), despite industry-leading profitability, identifying inefficient capital allocation and governance issues as primary driversAlign Partners outlines measures for capital efficiency and governance normalization; requests a revised “Value-up” plan and a formal response from the Board by March 6, 2026The proposals nominate two Independent Directors via separate election and calls for the reinstatement of the Internal Transaction Committee Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 13:00:00 CET | Press release
TarSeer™ BRETSA™ Target Engagement System enables studies for difficult proteins early in drug discovery Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 13:00:00 CET | Press release
Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom